Related references
Note: Only part of the references are listed.The altered enteroendocrine reportoire following roux-en-Y-gastric bypass as an effector of weight loss and improved glycaemic control
R. Charlotte Moffett et al.
APPETITE (2021)
Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes
Ryan A. Lafferty et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2021)
The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence
Mohammed Altigani Abdalla et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Emerging glucose-lowering therapies: a guide for cardiologists
Gaurav S. Gulsin et al.
HEART (2020)
Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study
Jeremy H. Pettus et al.
DIABETES CARE (2020)
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist
Victoria E. R. Parker et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic GiuCreERT2; ROSA26-eYFP mice
Dipak Sarnobat et al.
PEPTIDES (2020)
Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates
Patrick J. Knerr et al.
PEPTIDES (2020)
Intranasal Glucagon: A New Way to Treat Hypoglycemic Emergencies
Rachel N. Lowe et al.
ANNALS OF PHARMACOTHERAPY (2020)
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens
Juan Pablo Frias et al.
DIABETES OBESITY & METABOLISM (2020)
Essential Role of Syntaxin-Binding Protein-1 in the Regulation of Glucagon-Like Peptide-1 Secretion
Jhenielle R. Campbell et al.
ENDOCRINOLOGY (2020)
Oxyntomodulin and Glicentin May Predict the Effect of Bariatric Surgery on Food Preferences and Weight Loss
Mette S. Nielsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Oral semaglutide in type 2 diabetes
Sarah L. Anderson et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2020)
Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome
Diane M. Hargrove et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
Advances in oral peptide therapeutics
Daniel J. Drucker
NATURE REVIEWS DRUG DISCOVERY (2020)
Emerging role of GIP and related gut hormones in fertility and PCOS
R. Charlotte Moffett et al.
PEPTIDES (2020)
An overview of GLP-1 agonists and recent cardiovascular outcomes trials
Kelsey H. Sheahan et al.
POSTGRADUATE MEDICAL JOURNAL (2020)
Intra-islet GLP-1, but not CCK, is necessary for beta-cell function in mouse and human islets
Arnaldo Henrique de Souza et al.
SCIENTIFIC REPORTS (2020)
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Mark L. Hartman et al.
DIABETES CARE (2020)
Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetes
Neil Tanday et al.
JOURNAL OF ENDOCRINOLOGY (2020)
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Aaron S. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard et al.
JCI INSIGHT (2020)
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial
Serge A. Jabbour et al.
DIABETES CARE (2020)
Role of exendin-4 in the Gila monster: Further lessons regarding human oral glucagon-like peptide-1 therapy?
Galyna V. Graham et al.
DIABETES OBESITY & METABOLISM (2020)
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
David M. Williams et al.
DIABETES THERAPY (2020)
Antidiabetic drug therapy alleviates type 1 diabetes in mice by promoting pancreatic α-cell transdifferentiation
Dipak Sarnobat et al.
BIOCHEMICAL PHARMACOLOGY (2020)
GLP-1 receptor agonists for Parkinson's disease
Caroline A. Mulvaney et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2020)
Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis
Michelle L. Boland et al.
NATURE METABOLISM (2020)
Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current Advances and Future Directions
Annie Hasib
CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES (2020)
Targeted pharmacological therapy restores β-cell function for diabetes remission
Stephan Sachs et al.
NATURE METABOLISM (2020)
A Long-Acting PYY3-36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates
Shamina M. Rangwala et al.
CELL METABOLISM (2019)
Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment
Sine Paasch Schiellerup et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
The GLP-1 Receptor Agonist Exenatide Ameliorates Bone Composition and Tissue Material Properties in High Fat Fed Diabetic Mice
Sity Aishah Mansur et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Carolyn F. Deacon
FRONTIERS IN ENDOCRINOLOGY (2019)
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
Yi Han et al.
REPRODUCTIVE BIOMEDICINE ONLINE (2019)
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)
Grazia Daniela Femminella et al.
TRIALS (2019)
Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study
Preeshila Behary et al.
DIABETES CARE (2019)
Glucagon like peptide 2 has a positive impact on osteoporosis in ovariectomized rats
Bing'er Xu et al.
LIFE SCIENCES (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
Thomas R. Pieber et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial
Rahim M. Naimi et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men
Kirsa Skov-Jeppesen et al.
BONE (2019)
An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity
Simona Ferjan et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2019)
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
Ildiko Lingvay et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Sitagliptin Alters Bone Composition in High-Fat-Fed Mice
Sity Aishah Mansur et al.
CALCIFIED TISSUE INTERNATIONAL (2019)
Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus
Ulrike Hoevelmann et al.
DIABETES OBESITY & METABOLISM (2019)
Exendin-4(Lys27PAL)/gastrin/xenin-8-Gln: A novel acylated GLP-1/gastrin/xenin hybrid peptide that improves metabolic status in obese-diabetic (ob/ob) mice
Annie Hasib et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2019)
Liraglutide protects against glucolipotoxicity-induced RIN-m5F β-cell apoptosis through restoration of PDX1 expression
Edy Kornelius et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists
Guillaume Mabilleau et al.
JOURNAL OF ENDOCRINOLOGY (2018)
A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice
David C. Hornigold et al.
APPETITE (2018)
Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease
Jingjing Tai et al.
BRAIN RESEARCH (2018)
MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study
Philip D. Ambery et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study
Vesna Salamun et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln
Annie Hasib et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Philip Ambery et al.
LANCET (2018)
Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease
Dilan Athauda et al.
NEUROPHARMACOLOGY (2018)
GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes
Victor A. Gault et al.
PEPTIDES (2018)
Gut hormone polyagonists for the treatment of type 2 diabetes
Sara J. Brandt et al.
PEPTIDES (2018)
Newer GLP-1 receptor agonists and obesity-diabetes
Emily Brown et al.
PEPTIDES (2018)
Problem or solution: The strange story of glucagon
R. V. Scott et al.
PEPTIDES (2018)
Glucagon receptor signaling in metabolic diseases
Nicolai J. Wewer Albrechtsen
PEPTIDES (2018)
A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice
Annie Hasib et al.
PEPTIDES (2018)
Oxyntomodulin analogue increases energy expenditure via the glucagon receptor
R. Scott et al.
PEPTIDES (2018)
Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors (vol 8, 2018)
Oleg G. Chepurny et al.
SCIENTIFIC REPORTS (2018)
The Cells of the Islets of Langerhans
Gabriela Da Silva Xavier
JOURNAL OF CLINICAL MEDICINE (2018)
Glucagon-Like Peptide 1 Increases β-Cell Regeneration by Promoting α- to β-Cell Transdifferentiation
Young-Sun Lee et al.
DIABETES (2018)
Peptide-based multi-agonists: a new paradigm in metabolic pharmacology
S. J. Brandt et al.
JOURNAL OF INTERNAL MEDICINE (2018)
Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017
Samantha Wilkinson et al.
BMJ OPEN (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
The Role of PPAR-δ in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor
Yi Liu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Glucagon-related peptides from phylogenetically ancient fish reveal new approaches to the development of dual GCGR and GLP1R agonists for type 2 diabetes therapy
Galyna Graham et al.
PEPTIDES (2018)
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coskun et al.
MOLECULAR METABOLISM (2018)
Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial
Julio Rosenstock et al.
DIABETES CARE (2018)
Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog
Ulrike Hoevelmann et al.
DIABETES CARE (2018)
Beyond Glucagon-like Peptide-1: Is G-Protein Coupled Receptor Polypharmacology the Path Forward to Treating Metabolic Diseases?
Kyle W. Sloop et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2018)
Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study
Jean-Michel Petit et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome
Kishore R. Iyer et al.
JOURNAL OF PARENTERAL AND ENTERAL NUTRITION (2017)
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes A Randomized Clinical Trial
Melanie Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers
Tricia Tan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice
Paul Millar et al.
JOURNAL OF ENDOCRINOLOGY (2017)
GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice
Soren B. van Witteloostuijn et al.
JOURNAL OF PEPTIDE SCIENCE (2017)
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda et al.
LANCET (2017)
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
Carel W. le Roux et al.
LANCET (2017)
Differential expression of glucagon-like peptide-2 (GLP-2) is involved in pancreatic islet cell adaptations to stress and beta-cell survival
Dawood Khan et al.
PEPTIDES (2017)
THE NEW BIOLOGY AND PHARMACOLOGY OF GLUCAGON
T. D. Mueller et al.
PHYSIOLOGICAL REVIEWS (2017)
Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial
Malin Nylander et al.
REPRODUCTIVE BIOMEDICINE ONLINE (2017)
Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol
Surya Panicker Rajeev et al.
BMJ OPEN (2017)
Osteoporosis treatment: recent developments and ongoing challenges
Sundeep Khosla et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes
Cristina B. Guzman et al.
DIABETES OBESITY & METABOLISM (2017)
A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist
Eric L. Schneider et al.
ACS CHEMICAL BIOLOGY (2017)
The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
Anne Orgaard et al.
DIABETOLOGIA (2017)
Insights on glicentin, a promising peptide of the proglucagon family
Juliette Raffort et al.
BIOCHEMIA MEDICA (2017)
Evidence of Extrapancreatic Glucagon Secretion in Man
Asger Lund et al.
DIABETES (2016)
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12-and 24-Week Phase 2 Studies
Christof M. Kazda et al.
DIABETES CARE (2016)
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
Michael A. Nauck et al.
DIABETES CARE (2016)
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
V. Salem et al.
DIABETES OBESITY & METABOLISM (2016)
A new stable GIP-Oxyntomodulin hybrid peptide improved bone strength both at the organ and tissue levels in genetically-inherited type 2 diabetes mellitus
Sity Aishah Mansur et al.
BONE (2016)
High fat-fed diabetic mice present with profound alterations of the osteocyte network
Guillaume Mabilleau et al.
BONE (2016)
Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling
Emma Robinson et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Glucagon and heart in type 2 diabetes: new perspectives
Antonio Ceriello et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Gut hormone GPCRs: structure, function, drug discovery
Arnau Cordomi et al.
CURRENT OPINION IN PHARMACOLOGY (2016)
Clinical Trials, Triumphs, and Tribulations of Glucagon Receptor Antagonists
Mackenzie J. Pearson et al.
DIABETES CARE (2016)
Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
S. J. Henderson et al.
DIABETES OBESITY & METABOLISM (2016)
Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice
F. P. M. O'Harte et al.
DIABETES OBESITY & METABOLISM (2016)
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
Johan Jendle et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2016)
Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance
Kazimierz Wisniewski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice
F. P. M. O'Harte et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2016)
GLP-1 and estrogen conjugate acts in the supramammillary nucleus to reduce food-reward and body weight
Heike Vogel et al.
NEUROPHARMACOLOGY (2016)
In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial
Michael Gejl et al.
FRONTIERS IN AGING NEUROSCIENCE (2016)
Bariatric Surgery and Long-term Durability of Weight Loss
Matthew L. Maciejewski et al.
JAMA SURGERY (2016)
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
Juan P. Frias et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation
Aiysha Thompson et al.
PLOS ONE (2016)
Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation
Etienne Larger et al.
ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS (2016)
Alteration of the bone tissue material properties in type 1 diabetes mellitus: A Fourier transform infrared microspectroscopy study
Aleksandra Mieczkowska et al.
BONE (2015)
Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type2 Diabetes
Nigel Irwin et al.
CHEMMEDCHEM (2015)
A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice
Nigel Irwin et al.
DIABETES (2015)
Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide
S. Patterson et al.
DIABETES OBESITY & METABOLISM (2015)
Sustained treatment with a stable long-acting oxyntomodulin analogue improves metabolic control and islet morphology in an experimental model of type 1 diabetes
N. Irwin et al.
DIABETES OBESITY & METABOLISM (2015)
Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes
R. P. Kelly et al.
DIABETES OBESITY & METABOLISM (2015)
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline
V. A. Gault et al.
DIABETES OBESITY & METABOLISM (2015)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
Melanie J. Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus
Sity Aishah Mansur et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2015)
Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure
Jonatan Ising Bagger et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Glucagon receptor antagonism induces increased cholesterol absorption
Hong-Ping Guan et al.
JOURNAL OF LIPID RESEARCH (2015)
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Increased food intake with oxyntomodulin analogues
Samantha L. Price et al.
PEPTIDES (2015)
Vagal mediation of GLP-1's effects on food intake and glycemia
Jean-Philippe Krieger et al.
PHYSIOLOGY & BEHAVIOR (2015)
The role of enteric hormone GLP-2 in the response of bone markers to a mixed meal in postmenopausal women with type 2 diabetes mellitus
Laura S. Girao Lopes et al.
DIABETOLOGY & METABOLIC SYNDROME (2015)
Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes
Rachel Charlotte Moffett et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2015)
Ins1 Cre knock-in mice for beta cell-specific gene recombination
Bernard Thorens et al.
DIABETOLOGIA (2015)
GLP-1-oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice
Robert W. Schwenk et al.
DIABETOLOGIA (2015)
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Brian Finan et al.
NATURE MEDICINE (2015)
Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength
A. Mieczkowska et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Glicentin-related pancreatic polypeptide inhibits glucose-stimulated insulin secretion from the isolated pancreas of adult male rats
Lynda Whiting et al.
PHYSIOLOGICAL REPORTS (2015)
New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders
Nigel Irwin et al.
WORLD JOURNAL OF DIABETES (2015)
Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson's Disease
Iciar Aviles-Olmos et al.
JOURNAL OF PARKINSONS DISEASE (2014)
Albiglutide: A New GLP-I Receptor Agonist for the Treatment of Type 2 Diabetes
Jennifer M. Trujillo et al.
ANNALS OF PHARMACOTHERAPY (2014)
Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases
Christian Hoelscher
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
Effects of short-term chemical ablation of glucagon signalling by peptide-based glucagon receptor antagonists on insulin secretion and glucose homeostasis in mice
Zara J. Franklin et al.
BIOLOGICAL CHEMISTRY (2014)
Identification and Characterization of GLP-1 Receptor-Expressing Cells Using a New Transgenic Mouse Model
Paul Richards et al.
DIABETES (2014)
A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation
Aisling M. Lynch et al.
DIABETOLOGIA (2014)
Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
J. van Can et al.
INTERNATIONAL JOURNAL OF OBESITY (2014)
Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice
Rachael Lennox et al.
NEUROPHARMACOLOGY (2014)
Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice
Laura M. McShane et al.
PEPTIDES (2014)
Role of Endogenous GLP-1 and GIP in Beta Cell Compensatory Responses to Insulin Resistance and Cellular Stress
Srividya Vasu et al.
PLOS ONE (2014)
Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
Xing-Chun Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Hypothalamic PGC-1α Protects Against High-Fat Diet Exposure by Regulating ERα
Eugenia Morselli et al.
CELL REPORTS (2014)
Action and therapeutic potential of oxyntomodulin
Alessandro Pocai
MOLECULAR METABOLISM (2014)
(pGlu-Gln)-CCK-8[mPEG]: A novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes
Nigel Irwin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2013)
The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus
Angel Guzman-Perez et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality
Aleksandra Mieczkowska et al.
BONE (2013)
Enteroendocrine hormone mimetics for the treatment of obesity and diabetes
Nigel Irwin et al.
CURRENT OPINION IN PHARMACOLOGY (2013)
The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant?
Stefan Trapp et al.
CURRENT OPINION IN PHARMACOLOGY (2013)
A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice
V. K. Bhat et al.
DIABETOLOGIA (2013)
desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon: Long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity
Nigel Irwin et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice
W. D. Porter et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
Subcutaneous Administration of Liraglutide Ameliorates Alzheimer-Associated Tau Hyperphosphorylation in Rats with Type 2 Diabetes
Yan Yang et al.
JOURNAL OF ALZHEIMERS DISEASE (2013)
Exenatide and the treatment of patients with Parkinson's disease
Iciar Aviles-Olmos et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists
F. P. M. O'Harte et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-β Plaque and Glial Pathology in a Mouse Model of Alzheimer's Disease
Caitriona M. Long-Smith et al.
NEUROMOLECULAR MEDICINE (2013)
GDNF, NGF and BDNF as therapeutic options for neurodegeneration
Shelley J. Allen et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure
Carsten Askov-Hansen et al.
REGULATORY PEPTIDES (2013)
Estrogen, astrocytes and the neuroendocrine control of metabolism
E. Fuente-Martin et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2013)
Glucagon-like peptide 1 and appetite
Megan J. Dailey et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2013)
Long-acting preparations of exenatide
Yunpeng Cai et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
Impact of Diabetes on Cardiovascular Disease: An Update
Alessandra Saldanha de Mattos Matheus et al.
INTERNATIONAL JOURNAL OF HYPERTENSION (2013)
Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25
Christine M. A. Martin et al.
BIOCHEMICAL PHARMACOLOGY (2012)
A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity
Kevin J. Filipski et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents
Jonathan W. Day et al.
BIOPOLYMERS (2012)
Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion
H. E. Parker et al.
DIABETOLOGIA (2012)
Minireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in Diabetes
Philip E. Cryer
ENDOCRINOLOGY (2012)
Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia
Juho Lee et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2012)
Targeted estrogen delivery reverses the metabolic syndrome
Brian Finan et al.
NATURE MEDICINE (2012)
The Glucagon Receptor Is Involved in Mediating the Body Weight-Lowering Effects of Oxyntomodulin
Jennifer R. Kosinski et al.
OBESITY (2012)
Anti-Diabetic Efficacy and Impact on Amino Acid Metabolism of GRA1, a Novel Small-Molecule Glucagon Receptor Antagonist
James Mu et al.
PLOS ONE (2012)
Roux-en-Y gastric bypass ameliorates polycystic ovary syndrome and dramatically improves conception rates: a 9-year analysis
Mohammad Jamal et al.
SURGERY FOR OBESITY AND RELATED DISEASES (2012)
Aging and bone loss: new insights for the clinician
Oddom Demontiero et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2012)
Administration of an acylated GLP-I and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity
Victor A. Gault et al.
CLINICAL SCIENCE (2011)
Insulin effects in muscle and adipose tissue
George Dimitriadis et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome
P. B. Jeppesen et al.
GUT (2011)
Obesity 2 Health and economic burden of the projected obesity trends in the USA and the UK
Y. Claire Wang et al.
LANCET (2011)
Short bowel syndrome: A review of management options
Prasad Seetharam et al.
SAUDI JOURNAL OF GASTROENTEROLOGY (2011)
(D-Ser2)Oxm[mPEG-PAL]: A novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions
Barry D. Kerr et al.
BIOCHEMICAL PHARMACOLOGY (2010)
GLP-1 Inhibits and Adrenaline Stimulates Glucagon Release by Differential Modulation of N- and L-Type Ca2+ Channel-Dependent Exocytosis
Yang Z. De Marinis et al.
CELL METABOLISM (2010)
Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets
Kyle W. Sloop et al.
DIABETES (2010)
Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance
D. W. Porter et al.
DIABETES OBESITY & METABOLISM (2010)
Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has a Direct Role in Decreasing Hepatic Steatosis In Vitro by Modulating Elements of the Insulin Signaling Pathway
Nitika Arora Gupta et al.
HEPATOLOGY (2010)
The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria
Wendy A. March et al.
HUMAN REPRODUCTION (2010)
Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet
V. A. Gault et al.
INTERNATIONAL JOURNAL OF OBESITY (2010)
Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety
Ashley I. Taylor et al.
JOURNAL OF ENDOCRINOLOGY (2010)
Conversion of adult pancreatic α-cells to β-cells after extreme β-cell loss
Fabrizio Thorel et al.
NATURE (2010)
Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling
Aileen M. Moloney et al.
NEUROBIOLOGY OF AGING (2010)
A high-fat diet impairs neurogenesis: Involvement of lipid peroxidation and brain-derived neurotrophic factor
Hee Ra Park et al.
NEUROSCIENCE LETTERS (2010)
Paracrinology of islets and the paracrinopathy of diabetes
Roger H. Unger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides
Niels Vrang et al.
PROGRESS IN NEUROBIOLOGY (2010)
Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects
Jerry R. Greenfield et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2009)
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Alessandro Pocai et al.
DIABETES (2009)
Mechanisms of early improvement resolution of type 2 diabetes after bariatric surgery
G. Mingrone et al.
DIABETES & METABOLISM (2009)
Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice
N. Irwin et al.
DIABETES OBESITY & METABOLISM (2009)
Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications
N. Irwin et al.
DIABETOLOGIA (2009)
Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs
Maralyn R. Druce et al.
ENDOCRINOLOGY (2009)
Nutritional regulation of glucagon-like peptide-1 secretion
Gwen Tolhurst et al.
JOURNAL OF PHYSIOLOGY-LONDON (2009)
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Jonathan W. Day et al.
NATURE CHEMICAL BIOLOGY (2009)
Assessment and management of hypoglycemia in children and adolescents with diabetes
William Clarke et al.
PEDIATRIC DIABETES (2009)
Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on Intestinal Morphology and Absorption, Renal Function, Bone and Body Composition, and Muscle Function
P. B. Jeppesen et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2009)
Pramlintide in the Treatment of Diabetes Mellitus
Steve Edelman et al.
BIODRUGS (2008)
Glucose Sensing in L Cells: A Primary Cell Study
Frank Reimann et al.
CELL METABOLISM (2008)
Glucagon as a treatment of severe hypoglycemia - Safe and efficacious but underutilized
Teresa Pearson
DIABETES EDUCATOR (2008)
The murine glucagon-like peptide-1 receptor is essential for control of bone resorption
Chizumi Yamada et al.
ENDOCRINOLOGY (2008)
Pharmacokinetics, Safety, and Tolerability of Teduglutide, a Glucagon-Like Peptide-2 (GLP-2) Analog, Following Multiple Ascending Subcutaneous Administrations in Healthy Subjects
Jean-Francois Marier et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract
Ida B. Gottschalck et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2008)
GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet
Paula L. McClean et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Oxyntomodulin differentially affects glucagon-like peptide-1 receptor β-arrestin recruitment and signaling through Gαs
Rasmus Jorgensen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus
F. K. Knop et al.
DIABETOLOGIA (2007)
Small-molecule agonists for the glucagon-like peptide 1 receptor
Lotte Bjerre Knudsen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
Tina Vilsboll et al.
DIABETES CARE (2007)
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Maire E. Doyle et al.
PHARMACOLOGY & THERAPEUTICS (2007)
Exenatide - A review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea)
Risto S. Cvetkovic et al.
DRUGS (2007)
Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial
K. Wynne et al.
INTERNATIONAL JOURNAL OF OBESITY (2006)
Glucagon-like peptide 1 secretion by the L-cell - The view from within
Gareth E. Lim et al.
DIABETES (2006)
The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans
JJ Meier et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2006)
Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs
L Simonsen et al.
DIABETOLOGIA (2006)
Different metabolic responses in α-, β-, and δ-cells of the islet of Langerhans monitored by redox confocal microscopy
I Quesada et al.
BIOPHYSICAL JOURNAL (2006)
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans
J Schirra et al.
GUT (2006)
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
LA Nikolaidis et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients
PB Jeppesen et al.
GUT (2005)
Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk
P Vestergaard et al.
DIABETOLOGIA (2005)
Contraction induced by glicentin on smooth muscle cells from the human colon is abolished by exendin (9-39)
SE Ayachi et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2005)
β-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1
YH Li et al.
DIABETES (2005)
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
OG Kolterman et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2005)
Increased risk of type 2 diabetes in Alzheimer disease
J Janson et al.
DIABETES (2004)
PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates
ZJ Yang et al.
CANCER RESEARCH (2004)
Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid
BD Green et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2004)
Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure
LL Baggio et al.
GASTROENTEROLOGY (2004)
A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects
SA Qureshi et al.
DIABETES (2004)
On the physiology of GIP and GLP-1
JJ Holst
HORMONE AND METABOLIC RESEARCH (2004)
N-acetyl-GLP-1: a DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell-associated gene expression
HK Liu et al.
CELL BIOLOGY INTERNATIONAL (2004)
Role of gastrointestinal hormones in postprandial reduction of bone resorption
DB Henriksen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Effect of laparoscopic Roux-En Y gastric bypass on type 2 diabetes mellitus
PR Schauer et al.
ANNALS OF SURGERY (2003)
Oxyntomodulin suppresses appetite and reduces food intake in humans
MA Cohen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Role of luminal nutrients and endogenous GLP-2 in intestinal adaptation to mid-small bowel resection
EM Dahly et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2003)
Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis
YZ Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Short bowel syndrome and Crohn's disease
JS Thompson et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2003)
Glucose-sensing in glucagon-like peptide-1-secreting cells
F Reimann et al.
DIABETES (2002)
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes:: a parallel-group study
M Zander et al.
LANCET (2002)
Development of potent glucagon antagonists: structure-activity relationship study of glycine at position 4
JM Ahn et al.
JOURNAL OF PEPTIDE RESEARCH (2001)
Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells
HX Hui et al.
DIABETES (2001)
Glucagon-like peptide 2: A nutrient-responsive gut growth factor
DG Burrin et al.
JOURNAL OF NUTRITION (2001)
Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon
PB Jeppesen et al.
GASTROENTEROLOGY (2001)
Cognition and synaptic plasticity in diabetes mellitus
WH Gispen et al.
TRENDS IN NEUROSCIENCES (2000)
Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse
MA Benjamin et al.
GUT (2000)
New frontiers in the biology of GLP-2
J Lovshin et al.
REGULATORY PEPTIDES (2000)
Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon -: Characterization of glucagon degradation products and DPIV-resistant analogs
SA Hinke et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
